2023年5月2日

ODAIA——MAPTUAL背后的公司,一个AI-powered商业见解SaaS平台制药公司宣布,它提出了一个超额认购2500万美元系列B轮融资门槛企业和共同的专著。和卫丁顿企业也从现有投资者弗林特资本与参与,BDC资本的女性在技术风险基金,立企业,以及石墨企业。艾米丽·梅尔顿、阈值的管理合伙人企业和查尔斯•康涅狄格州专著的联合创始人和合伙人企业,将加入ODAIA董事会与资金。梅根·凯利,阈值的主要企业,也将加入董事会观察员。通过一个能够提供接近实时的和预测的角度对医药市场的动态变化,ODAIA专有平台MAPTUAL赋予领先的生命科学品牌更有效地得到治疗,药物和疫苗市场需要用现代的数据驱动的解决方案。全球大流行展示关键数据需要采取新的策略,客户细分,并在药品品牌体验。并通过其令人印象深刻的预测技术,领先ODAIA解锁更聪明的方式为生命科学公司与客户和带来更好的病人护理。公司数量排名前20位的几个全球制药公司客户和年度经常性收入(ARR)同比增长超过646%,在2022年ODAIA正在改变与其引领产品MAPTUAL医药营销和商业化。MAPTUAL MAPTUAL被称为一个SaaS平台,利用人工智能简化和自动化勘探,排位赛,和参与的医疗服务提供者(HCP),这一过程主要是手工的,劳动密集型的,耗时。首先,品牌已经在快速的数据自动化新员工培训。 Then the AI models analyze data within hours to deliver actionable insights to reps, their managers, and marketers. And insights include a robust understanding of the relevant providers and the patients they are treating, brand and market forecasts, target curation and prioritization for call planning, and an understanding of the most effective channels to reach those targets. But no other platform puts so much information in front of pharma commercial teams so they can make solid data-driven decisions with near-real-time data and insights. MAPTUAL was engineered for taking the guesswork out of Pharma’s current workflow by unifying commercial teams through digestible and actionable predictive insights. And its two products MAPTUAL Field and MAPTUAL Sphere are built on an easy-to-navigate platform that provides a near-real-time and predictive perspective on a brand and its market; MAPTUAL Field essentially provides sales reps with a granular view of healthcare providers, allowing pharma sales reps to use robust segments, and prescription data – both historical and predicted – to improve their pre-call planning and spend more time seeing customers rather than analyzing data. MAPTUAL Sphere enables sales managers to effectively coach their team by discussing territory brand and market dynamics and HCP channel preferences. And marketers are also able to understand the contribution of different channels, by HCP segment, on prescription trends to make a better marketing strategy and execution decisions. And using MAPTUAL Field and MAPTUAL Sphere together allows for tailored insights to be delivered to the right teams while ensuring consistency in analytics and data sources, and ultimately leading to better and timely patient care. KEY QUOTES: “ODAIA’s ability to constantly ingest and update a broad mix of life sciences data and turn it into comprehensive insights in near-real-time turns pharmaceutical sales from reactive to proactive. We’re thrilled to lead their Series B financing. ODAIA helps get life-changing drugs into the hands of those who need them faster and more efficiently.” Emily Melton, Managing Partner at Threshold Ventures “ODAIA has built impressive AI solutions that provide the pharmaceutical industry with the resources needed for the modern age. We’re confident that this latest round of funding will further empower their impressive team to quickly scale their offering, which will benefit those who rely on therapeutics for their health and wellbeing.” Charles Conn, Partner at Monograph Ventures “Even in a challenging funding environment, our valued investors clearly recognized the significant problem we’re solving for the pharmaceutical industry. With these funds, we’ll continue to evolve our product and build out our team to ensure we’re able to offer our existing and future life science brands the predictive tools needed for today’s market, and tomorrow’s. It’s our pleasure to welcome these investors to the ODAIA team.” Philip Poulidis, CEO and Co-Founder of ODAIA Trending on Pulse 2.0